Phase 3 Liver Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are willing to take part and have signed a consent form agreeing to participate in the study
- Adults aged 18 to 75 years old (male or female)
- People who have been diagnosed with hepatocellular carcinoma (a type of liver cancer) confirmed by tissue testing
- People who had surgery to fully remove the liver tumour (called R0 resection) between 4 and 8 weeks before joining the trial, with no cancer left behind at the edges
- People who have at least one of the following features that put them at higher risk of the cancer coming back after surgery: more than 3 tumours with at least one larger than 3 cm; a single tumour 5 cm or larger; signs of cancer cells found in blood vessels during or after surgery; cancer cells that look very abnormal under a microscope (low differentiation); the tumour capsule was invaded or had unclear borders; or the tumour had grown into nearby organs
- People with a good general health and liver function, as measured by specific scoring systems used by doctors (ECOG score of 0–1 and Child-Pugh score of 5–6)
- People who have not previously received any anti-cancer treatment for this liver cancer, except for up to 1–2 optional preventive procedures (TACE or HAIC) performed 4–8 weeks after surgery (confirm with trial site)
Who may not be able to join:
- People whose liver cancer is a specific rare type, such as sarcomatoid hepatocellular carcinoma, mixed liver-bile duct cancer, or fibrolamellar hepatocellular carcinoma
- People who have had another type of cancer in the past 5 years or are currently dealing with another cancer at the same time
- People with serious problems affecting other major organs such as the heart, brain, lungs, or kidneys
- People with a history of immune system problems or autoimmune diseases (conditions where the immune system attacks the body)
- People who show signs that the cancer has already come back or spread before joining the trial
- People who are known to be allergic to the study drug's ingredients, or who have had a severe allergic reaction to similar types of medicines (monoclonal antibodies or anti-angiogenic drugs)
- People who have a history of hepatic encephalopathy (a condition where the liver is unable to remove toxins, affecting brain function)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 15989187352
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
1 year recurrence-free survival rate ,1-year RFSR.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 13 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.